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Abstract
Introduction: Postoperatively diagnosed papillary or follicular thyroid cancer in subtotally thyroidectomised patients requires a comple-
tion thyroidectomy. Re-operation with a gamma probe can be particularly useful in these patients.
The aim of this study was to evaluate the benefits of using an intraoperative hand-held gamma detector during completion thyroidectomy 
in patients with well-differentiated thyroid cancer (WTC).
Material and methods: 75 patients with WTC qualified for total re-thyroidectomy. In 43 patients, Group I (Nav), a hand-held gamma 
probe (Navigator GPS) was used intraoperatively. 32 patients were re-operated without the gamma probe (Group II). In Group I, thyroid 
remnants were removed based on counted gamma signals. To estimate the radicality of reoperation in both groups, thyroglobulin (Tg) 
levels were determined and total body scanning (TBS) — I131 uptake — was performed.
Results: Total thyroidectomy with central lymphadenectomy was performed in 75 cases. The average level of Tg and iodine uptake after 
radicalisation was lower in Group I (Nav) than in Group II (3.32 ± 2.09 v. 4.58 ± 2.5 ng/mL, respectively, for Tg [p = 0.021] and 6.29 ± 
3.38 v. 7.31 ± 2.29 ng/mL, respectively, for iodine uptake [p = 0.187]). Additionally, the frequency of postoperative complications was 
comparable, the difference in both groups was not significant, despite the use of the gamma probe (p = 0.109).
Conclusions: The intraoperative use of a hand-held gamma detector can help to improve the radicality of a completion thyroidectomy 
procedure after an incomplete primary thyroid resection, but the results of this procedure in the hands of an experienced surgeon are 
comparable whether or not the gamma detector is used. (Endokrynol Pol 2013; 64 (5): 335–339)
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Streszczenie
Wstęp: Rozpoznanie po operacjach pierwotnie niedoszczętnych raka brodawkowatego lub pęcherzykowego tarczycy wymaga radykali-
zacji leczenia operacyjnego i usunięcia całego gruczołu tarczowego. W zmienionych przez tkankę bliznowatą warunkach anatomicznych 
radykalność tych zabiegów może być niezadowalająca i w konsekwencji wpływać na wyniki tarapii.
Celem pracy była ocena korzyści wynikających z zastosowania ręcznego gamma nawigatora w zabiegach wtórnie całkowitych w przy-
padkach dobrze zróżnicowanych raków tarczycy. 
Materiał i metody: W pracy przedstawiono 75 przypadków chorych z dobrze zróżnicowanymi rakami tarczycy, zakwalifikowanych do 
radykalizacji leczenia operacyjnego. W 43 przypadkach (grupa I) śródoperacyjnie zastosowano ręczny gamma nawigator (Navigator 
GPS), 32 chorych reoperowano bez użycia wyżej wymienionego urządzenia (grupa II). W celu oceny radykalności wtórnie całkowitego 
zabiegu w obu grupach chorych badano pooperacyjnie stężenie tyreoglobuliny (Tg) oraz oceniano wyniki badania scyntygrafii całego 
ciała (I131) — jodochwytność. W obu grupach porównano również wystąpienie powikłań po zabiegach wtórnie radykalnych.
Wyniki: Podczas radykalizacji we wszystkich przypadkach wykonano całkowite wycięcie gruczołu tarczowego wraz z wycięciem węzłów 
chłonnych przedziału centralnego. Pooperacyjne średnie stęzenie Tg oraz jodochwytność były niższe w grupie I w porównaniu z grupą 
II: (3,32 ± 2,09 v. 4,58 ± 2,5 ng/ml, [p = 0,021] jodochwytność: 6,9 ± 3,38 (grupa I) v. 7,31 ± 2,29 ng/ml (grupa II) [p = 0,187]). Użycie 
nawigatora nie miało wpływu na częstość wystąpienia pooperacyjnych powikłań w obu grupach chorych (p = 0,109).
Wnioski: Śródoperacyjne zastosowanie nawigatora może być pomocne w osiągnięciu lepszej radykalności pierwotnie nieradykalnych 
operacji, chociaż obserwowane wyniki pozwalają na stwierdzenie, że zabieg ten wykonywany przez doświadczonego operatora 
pozwala na osiągnięcie porównywalnej radykalności niezależnie od śródoperacyjnej detekcji izotopowej. 
(Endokrynol Pol 2013; 64 (5): 335–339)
Słowa kluczowe: dobrze zróżnicowane raki tarczycy, zabiegi wtórnie całkowite, gamma nawigator, jodoradioterapia
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Introduction
The treatment of thyroid cancer is a multilevel and 
interdisciplinary process involving not only the surgi-
cal procedure, but also isotope I131 therapy, hormone 
therapy, radiotherapy, and, in rare cases, chemotherapy. 
Specific guidelines have been prescribed by surgical 
and thyreological associations (e.g. the American Thy-
roid Association or Deutsche Gesselschaft für Chirurgie); 
according to them, the recommended treatment is 
a total extracapsular thyroidectomy with removal of 
lymph nodes of the central neck compartment and of 
the upper mediastinum (groups VI and VII) and total 
thyroidectomy is defined as a gland resection after 
which the remaining thyroid parenchyma is less than 
1 ml on each side [1–3].
After anything less than radical treatment, there is 
a recommendation to perform the second surgery that 
involves total removal of the thyroid. A radical opera-
tion with intraoperative radioisotopic examination is 
considered when iodine uptake after 24 hours does 
not exceed 1% [4–6]. Unfortunately, there is a group 
of patients in whom, after a macroscopically-radical 
operation, the postoperative scintiscanning performed 
one month after surgery shows the presence of remnant 
thyroid tissue [7–9] or due to difficulties in preoperative 
diagnosis of thyroid cancer, primary radical treatment 
was not considered to be needed. In such cases, it is 
necessary to perform a secondary radical operation. 
The completeness of these types of operations is often 
doubtful and there is a higher risk of postoperative 
complications [10, 11]. According to the literature, 
the use of intraoperative scintiscanning (via a gamma 
detector) can improve the radicality of the secondary 
operation and thus should increase the percentage of 
long-term survivors [11, 12].
The aims of the study were: 
 — To assess the usefulness of an intraoperative gamma 
detector in patients requiring a completion thyroid-
ectomy
 — To analyse the presence of cancer in thyroid rem-
nants in patients after the original non-radical 
surgery
Material and methods
Seventy-five patients underwent re-operation between 
2006 and 2011 because of a diagnosis of WTC (well-dif-
ferentiated thyroid cancer) in the final histopathological 
examination. Of these, 43 patients were operated on 
with the assistance of an intraoperative gamma detec-
tor (Navigator GPS [Gamma Positioning System, Tyco 
Healthcare Group, USA]): this group we call Group I 
(Nav). The 32 remaining patients were re-operated on 
using standard surgical technique without the use of 
a gamma detector: this group we call Group II. Patients 
were randomly assigned to either Group I (Nav) or II.
All 75 analysed patients were originally operated 
on because of a nodular goitre and initially underwent 
a subtotal thyroidectomy. In all cases, histopathological 
examination revealed WTC. In Group I (Nav), the his-
topathological examination revealed PTC in 30 patients 
and FTC in 13 patients, whereas in Group II such an 
examination revealed PTC in 26 patients and FTC in six 
patients (p = ns; Chi2 test). 
Due to the size of the cancer focus (≥ 1 cm) or the 
multifocal presentation, all patients were qualified for 
secondary surgical treatment within 2-3 months of the 
primary treatment.
Primary tumours were staged according to the 
Union for International Cancer Control (UJCC) pTNM 
classification. In Group I (Nav), there were 11 patients 
of stage T1 (26%), 30 of T2 (70%), one of T3 (2%) and one 
of T4 (2%) classification. In Group II there were seven 
patients of stage T1 (22%) and stage T2 (78%) classifica-
tion (p = ns; U-Mann-Whitney test).
In Group I (Nav), 1–2 mCi of I131 was administrated 
orally one day before surgery. An intraoperative gamma 
detector was used with a 10-mm scintillation probe. 
This detector is a portable, battery-operated device 
used for the detection of gamma radiation photons 
generated during radio decay. It enables the identifica-
tion and quantitative assessment of gamma radiation 
from isotopes localised inside the body and its tissues. 
Therefore, it is a non-imaging technique that involves 
the counting of radionuclides absorbed by individual 
organs. Obtained counts are based on the comparative 
measurement of radiopharmaceutical uptake in two or 
more areas of interest. During the secondary radical 
procedures, the radioactivity was counted in the neck 
and background/reference radioactivity was counted in 
the left shoulder. High counts indicated the presence 
of accumulating tissue I131. Thyroid tissue remnants 
were excised according to the scintillation counts. The 
probe was also used for the detection of individual 
lymph nodes and groups of lymph nodes before and 
after the excision. Collected specimens were then sent 
for histopathological verification.
In our study, a low dose 1–2 mCi of I131 was used 
during the intraoperative procedure and the count 
time length from the residual thyroid tissue was ten 
seconds. Administration of such a small dose of I131 al-
lows for its rapid elimination and does not impair the 
scintigraphy (TBS) performed six weeks after surgery. 
For the first 24 hours, 90% of the non-accumulated 
dose is excreted, followed by 5% on the second and 
third days. Accumulation of radioiodine in the thyroid 
gland can be detected within ten half-lives, but after 
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five weeks it usually remains at less than 1% of the 
administered dose.
All of the re-thyroidectomy cases were performed by 
one surgical team well-experienced in thyroid surgery. 
Early result evaluation involved the presence of postop-
erative complications specific to thyroid surgery: paresis 
or palsy of the laryngeal nerve and hypocalcaemia. 
The radicality of the second surgery was assessed 
by a radioiodine uptake test of the neck and by TBS 
performed 4–8 weeks after surgery under the condition 
of endogenous TSH stimulation. Dispersed radioiodine 
accumulation was considered not significant when 
it was less than 1%. Thyroglobulin (Tg) levels in the 
serum were also compared to estimate the radicality of 
completion thyroidectomy in both groups.
The study was approved by the Local Ethical Com-
mittee at the Medical University of Gdańsk. Patients 
signed informed consent forms and were blinded to 
the result of the randomisation. Patients from Group 
II received a placebo pill on the preoperative day and 
were treated under the same safety regimen as patients 
from Group I (Nav). Early results and complications 
were evaluated by members of the team blinded to 
the result of the randomisation. The evaluators of the 
long-term results (radioiodine uptake test and Tg level) 
were also blinded to the result of the randomisation. 
Statistical analysis was conducted using STATISTICA 
9.0 PL software licensed to the Medical University of 
Gdansk and included use of the Student t-test, Chi2 
test. A p value < 0.05 was considered as a statistically 
significant. The conducted study was prospective and 
randomised. 
Results
In both groups, excision of thyroid tissue remnants and 
central (compartments VI and VII) lymphadenectomy 
was performed in all patients. 
Analysis of pooled complications (postoperative 
hypocalcaemia and paralysis or palsy of the laryngeal 
nerve) revealed a comparable number of these com-
plications in Group I (Nav) versus Group II: there was 
no statistically significant difference (p = 0.109). Also 
analysis of postoperative hypocalcaemia did not reveal 
a statistically significant difference in total calcium levels 
between these two groups (p = 0.526) 
Average values of Tg after radicalisation in Group I 
(Nav) were 3.32 ± 2.09 ng/mL and in Group II were 4.58 
± 2.5 ng/mL (p = 0.021). The reference Tg value, based 
on normal physiological conditions, should not exceed 
52 ng/mL (79 pmol/U), and after total thyroidectomy the 
level of Tg is close to or equals 0 ng/mL (Fig. 1).
In the control TBS performed 4–8 weeks after surgi-
cal radicalisation, the difference in average J131 uptake in 
Group I versus Group II was not statistically significant 
(6.29 ± 3.38% v. 7.31 ± 2.29%, respectively; p = 0.187) 
(Fig. 2).
In our analysed group of 75 patients, histopathologi-
cal examination detected malignancy in 10% of thyroid 
remnants in Group I (Nav) (PTC in three patients [6%] 
and FTC in one patient [3%]). In the remaining 39 pa-
tients (91%), normal thyroid gland tissue was found. In 
Group II, malignancy was detected in 21% of excised 
remnants (all seven cases of PTC), while normal thyroid 
gland tissue was confirmed in the remaining 25 cases 
(79%) (Fig. 3).
Figure 1. Results of completion thyroidectomy: Tg level, t-Student 
test, p = 0.021
Rycina 1. Wyniki radykalizacji usunięcia tarczycy: stężenie 
tyreoglobuliny po zabiegach z wykorzystaniem lub bez 
wykorzystania GPS Navigatora. Analiza testem t-Studenta 
p = 0,021
Figure 2. Results of completion thyroidectomy: radioiodine uptake, 
t-Student test, p = 0.1875
Rycina 2. Wyniki radykalizacji usunięcia tarczycy: stopień 
jodochwytności po zabiegach z wykorzystaniem lub bez 
wykorzystania GPS Navigatora. Analiza testem t-Studenta 
p = 0,1875
338
PR
A
C
E 
O
RY
G
IN
A
LN
E
Completion thyroidectomy of well-differentiated cancer  Monika Proczko et al.
Discussion
Subtotally thyroidectomised patients finally diagnosed 
with WTC should undergo completion thyroidectomy 
[3]. Findings of possible remaining cancer foci in the 
thyroid remnants support this approach [13–15]. More-
over, this statement allows also for better postoperative 
monitoring and even makes adjuvant I131 unnecessary 
[9,10,13,16]. Unfortunately, the total remnants removal 
in scar tissue is technically difficult. Identification and 
precise localisation of the residual thyroid tissue and the 
evaluation of the completeness of resection are prob-
lematic. Re-thyroidectomies are also associated with 
a higher risk of postoperative complications [17–19]. 
Opponents of completion thyroidectomy argue that 
long-term results of WTC treatment are satisfactory, 
and that the survival rate does not increase in totally 
thyroidectomised patients. Rossi et al., Cady et al., 
Simpson et al., and Grant et al. argue that radicalisa-
tion only carries unnecessary complications [9, 20–22]. 
The timing of completion thyroidectomy is of the 
highest importance: the best time is within five days of 
the first operation or 2–3 months later [18,19]. Patients 
from the analysed groups were re-operated within 8–16 
weeks (mean: 11 weeks).
The usefulness of an intraoperative gamma probe is 
not unanimously agreed. Doubts result from differences of 
physical properties and methodology including the type 
of isotope used, timing of measurement, and the type of 
device used. The issue has been raised that if radio decay is 
a random phenomenon, the counts made in a short period 
of time may not be representative and thus false-positive 
results may be obtained [23–25]. In our study it was based 
on counts obtained with the probe held stationary in 
a similar position on each of the measured areas and on 
a comparison of the counts obtained from each area. 
Iodine uptake by thyroid tissue remnants is normally 
low, and that of cancer tissues is almost undetectable. 
According to the literature, the thyroid gland captures 
1–1.75% of I131 per gram of thyroid tissue. In cases of WTC, 
the uptake is lower than 0.5% per gram [23, 26, 27]. This 
may result in limited effectiveness of adjuvant radioiodine 
therapy and further legitimates the radical approach both 
in the primary and secondary surgical treatment.
Removing the entire thyroid gland seems to be an 
essential element of therapy. It makes the blood serum 
Tg concentration a sensitive and specific marker of 
the radicality of the surgical treatment and potential 
cancer recurrence [15, 16]. A Tg level below 2 ng/mL is 
considered undetectable and is associated with a virtual 
lack of thyroid tissue. In Group I (Nav), the Tg level was 
lower than 2 ng/mL in 28 patients (65%), and 2–8 ng/ 
/mL in the remaining 15 patients. The overall Group I 
mean Tg level was 3.32 ± 2.09 ng/mL, compared to the 
reference value in normal euthyroid patients of up to 
40 ng/mL, the mean Tg level in Group II was 4.58 ± 
± 2.5 ng/mL. The difference between Group I (Nav) 
and Group II was statistically significant (p = 0.021).
These results are evidence that better radicality 
is achieved during secondary treatment if an intra-
operative gamma detector is used. [28–30]. Ablation 
therapy is not at all necessary when iodine uptake after 
24 hours (T24 h) is less than 1–3% [25–28]. Iodine up-
take > 1%/3% is an indication for adjuvant radioiodo-
therapy. Achieving a control result of iodine uptake at 
T24 h < 1% is difficult or simply impossible even in the 
best surgical centres [30]. 
According to the European Association of Nuclear 
Medicine (EANM), ablative treatment I131 should be 
provided in all cases of WTC, even in cases of micro-
cancer if: (i) there is a history of ionising radiation; (ii) 
it is a diffuse sclerosing variant of PTC; or (iii) thyroid 
capsule infiltration is observed on histopathological ex-
amination. The statement of the European Thyroid As-
sociation (ETA) is more liberal and recommends ablative 
treatment after total thyroidectomy only in T3–4 stages 
of primary tumour or in cases of metastases to lymph 
nodes (N1). Experience in Poland suggests I131therapy 
also for pT1b-T2,N0,M0 cases [26, 33].
In our study, scintigraphy of the whole body was 
carried out with the evaluation of iodine uptake in both 
groups of patients at six weeks after the completion sur-
gery. In Group I, average iodine uptake was 6.29 ± 3.38%, 
whereas in Group II, iodine uptake was 7.31 ± 2.29% 
(p = 0.187). According to standard recommendations in 
Poland, 51 (68%) patients from both examined groups 
were qualified to the ablative treatment with I131.
Another important issue supporting the radical 
approach to re-thyroidectomy is highlighted by the 
reports of malignant lesions found in remnants that 
were removed during the second surgery. Levin et 
al. detected cancer foci in remaining tissue in 22% of 
re-operated patients [34]. In our analysed group of 
Figure 3. Histopathological results after completion thyroidectomy 
in Groups I (Navi) and II, Ch2 with Fisher correction p > 0.500
Rycina 3. Wynik histopatologiczny z materiału usuniętego 
w trakcie zabiegu wtórnego w grupach I (Navi), II. Analiza testem 
Chi2 z poprawką Fishera p > 0.500
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75 patients, histopathological examination detected 
malignancy in 9% of thyroid remnants in Group I (Nav). 
In Group II, malignancy was detected in 21% of excised 
remnants (all PTC), while normal thyroid gland tissue 
was confirmed in the remaining 25 cases (79%). 
There is no question that completion thyroidectomy 
is most beneficial in cases with multifocal cancer presen-
tation. According to the literature, the risk of recurrence 
in the contralateral lobe is 5-24% [4, 13–15]. Among the 
ten patients (26%) from both analysed groups, in whom 
foci of WTC were detected in thyroid remnants, there 
were also two cases in whom malignancy was revealed 
in the stump of the contralateral lobe. 
The percentage of thyroid surgery complications 
is higher in patients operated primarily for thyroid 
cancer; laryngeal nerve damage is observed in 3.3–6.4% 
and hypocalcaemia in 1.6–5.4% of patients. These rates 
are increased in secondary operations, 3.0-10.8% for 
laryngeal nerve injury and hypocalcaemia up to 30–50% 
[17–19, 24, 34]. 
In our study, we observed in three patients (6.97%) 
a transient paresis of laryngeal nerve, and permanent 
palsy in one case (2.3%). Also the frequency of postoper-
ative hypocalcaemia did not differ significantly between 
the two groups in our study. This phenomenon is nor-
mally observed in as much as 50% of thyroidectomies, 
and in more than 14% of cases it is permanent [35–37]. 
Conclusion
Completion thyroidectomy with the use of an intraop-
erative gamma detector can allow for better radicality 
of the surgical procedure. This enables the detection of 
the thyroid tissue with potential cancer foci, which are 
not macroscopically identifiable otherwise among scar 
tissue. On the other hand, a completion thyroidectomy 
procedure carried out by an experienced surgeon can 
be both radical and safe enough even without using 
a gamma hand probe. 
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